Kyowa Kirin Pharmaceutical Development Ltd.
Clinical Trials
23
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT05455931
- Locations
- 🇺🇸
The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Colombia University Medical Center, New York, New York, United States
A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
- Conditions
- X-Linked Hypophosphatemia
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 25
- Registration Number
- NCT05181839
- Locations
- 🇫🇷
Centre Hospitalier Universitair de Lille, Lille, France
🇫🇷Hospices Civils De Lyon, Lyon, France
🇫🇷APHP Paris - Assistance Publique Hopitaux de Paris, Paris, France
A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH
- Conditions
- X-Linked Hypophosphataemia
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT04819490
- Locations
- 🇬🇧
Royal Hospital for Sick Children, Edinburgh, United Kingdom
🇬🇧NHS Greater Glasgow & Clyde- South Glasgow University Hosp Division, Glasgow, United Kingdom
🇬🇧Leeds Teaching Hospitals NHS Trust, Trust Headquarters, St. James's University Hospital, Leeds, United Kingdom
Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT04188964
- Locations
- 🇦🇹
Kepler Universitaetsklinikum GmbH, Linz, Austria
🇫🇷Centre de reference des maladies renales rares-Hospices Civils de Lyon-Hopital Femme Mere Enfant, Lyon, France
🇫🇷Hopital Kremlin APHP, Paris, France
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 35
- Registration Number
- NCT03920072
- Locations
- 🇫🇷
CHU de Bicetre, Le Kremlin-Bicêtre, France
🇫🇷Hopital Lariboisiere, Paris, France
🇫🇷Hopital Cochin, Paris, France
- Prev
- 1
- 2
- 3
- Next